Alpine Woods Capital Investors’s Clovis Oncology, Inc. CLVS Stock Holding History

Alpine Woods Capital Investors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,000	Closed	-$247K	–	474
2017 Q3	$247K	Hold	3,000	–	–	0.01%	395
2017 Q2	$281K	Sell	3,000 -3,000	-50%	-$184K	0.02%	371
2017 Q1	$382K	Hold	6,000	–	–	0.02%	342
2016 Q4	$267K	Hold	6,000	–	–	0.01%	377
2016 Q3	$216K	Buy	+6,000	New	+$129K	0.01%	385
2016 Q1	–	Sell	-6,000	Closed	-$210K	–	465
2015 Q4	$210K	Hold	6,000	–	–	0.01%	418
2015 Q3	$552K	Hold	6,000	–	–	0.03%	316
2015 Q2	$527K	Buy	+6,000	New	+$514K	0.03%	314

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Alpine Woods Capital Investors's CLVS Position: Q4 2017 in Review

Alpine Woods Capital Investors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2017, closing a stake of 3,000 shares — an estimated $247K sold.

Alpine Woods Capital Investors first reported a position in CLVS in Q2 2015 and held it in 8 quarters. The position peaked at $552K in Q3 2015. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

Alpine Woods Capital Investors reported no remaining Clovis Oncology, Inc. position as of Q4 2017 after selling out during the quarter.
Alpine Woods Capital Investors sold 3,000 Clovis Oncology, Inc. shares in Q4 2017, an estimated $247K.
Alpine Woods Capital Investors first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 8 quarters.
Alpine Woods Capital Investors's Clovis Oncology, Inc. position peaked at $552K in Q3 2015.
247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2017, filed 14 Feb 2018.